BioLife Solutions, Inc..
BLFS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
BioLife Solutions, Inc. is a leading developer, manufacturer, and supplier of biopreservation media and related equipment for cells, tissues, and organs. Their products are used in the regenerative medicine, cell and gene therapy, and biopharmaceutical markets to preserve biological material during ...Show More
Better Health for All
20
BioLife Solutions' core products, including biopreservation media and cold chain management systems, are critical enablers for cell and gene therapies used to treat severe conditions like cancer, rare diseases, and genetic disorders.
1
These products are utilized in over 700 customer clinical applications and 17 commercial therapies, indicating a revolutionary positive health impact.
2
The company's products are not associated with established negative health outcomes.
3
BioLife Solutions reported $1 million in R&D expenses in Q1 2025 against Q1 2025 revenue of $23.9 million, which is approximately 4.18% of revenue.
4
This percentage does not meet the threshold for positive scoring in health innovation investment. The company does not hold healthcare-related patents or intellectual property, making the pharma patent flexibility KPI not applicable.
Fair Money & Economic Opportunity
0
No evidence available to assess BioLife Solutions, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
For fiscal year 2024, the company's CEO-to-median employee pay ratio was 58:1, with the median employee pay at $122,390.
1
Employee satisfaction, based on an average rating of 3.7 out of 5 stars from 33 reviews, indicates an engagement score of approximately 74/100.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess BioLife Solutions, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No evidence available to assess BioLife Solutions, Inc. on Honest & Fair Business.
Kind to Animals
0
No specific, concrete data points were found in the provided articles for BioLife Solutions, Inc. regarding any of the 'Kind to Animals' KPIs. While Article 4 mentioned a pre-clinical animal study planned for 2010.
1
This is a forward-looking statement from the past and not evidence of current animal testing volume or policy. Article 2 mentioned 'non-animal testing methods were employed in Good Laboratory Practice (GLP)-compliant in-vivo studies' but immediately followed by 'The study used immunocompromised mice', which is contradictory and does not provide quantifiable evidence of the extent of non-animal method *replacement* of animal testing.
2
Article 0 discussed the *potential* of human-derived alternatives to fetal bovine serum (an animal-derived ingredient) in a research context, but did not state that BioLife Solutions has implemented these alternatives in its products or replaced a specific percentage of animal-derived inputs.
3
Therefore, no KPIs could be scored based on the available evidence.
No War, No Weapons
0
BioLife Solutions, Inc. is explicitly stated to have "No Military Contracting" and "No Controversial Weapons" in multiple articles.
1
This indicates that the company derives 0% of its revenue from arms or defense contracts, has no exposure to controversial or banned weapons, and therefore has no defense-related assets to divest.
Planet-Friendly Business
0
No specific, quantitative data for BioLife Solutions, Inc. (BLFS.US) regarding its planet-friendly business practices could be found in the provided articles. explicitly states a lack of publicly available data for all relevant KPIs.
1
discusses sustainability initiatives, waste reduction, and net-zero targets, but these are attributed to "BioLife Plasma Services," which is a subsidiary of Takeda Pharmaceutical Company, not BioLife Solutions, Inc.
2
Therefore, the information in is not applicable to the company being assessed.
Respect for Cultures & Communities
0
No information relevant to BioLife Solutions, Inc.'s respect for cultures and communities, or any of the specified KPIs, was found in the provided articles.
1
The articles primarily consisted of job postings and recruitment information for either BioLife Plasma Services or West Fargo Public Schools, or general company culture information for BioLife Solutions, Inc., none of which contained specific data points for community engagement, cultural impact, or related metrics.
2
Safe & Smart Tech
-10
BioLife Solutions, Inc. experienced one immaterial security breach in Q3 2022, which involved redirecting payments to unauthorized accounts.
1
The company has a cybersecurity risk management process, including an incident management team and external expert consultation.
2
Its privacy policy, last updated August 23, 2018, outlines user rights to access, correct, erase, and transfer their data.
3
Data retention is for as long as necessary for business purposes, legal obligations, or potential litigation.
4
The company's policy also states compliance with GDPR and California privacy laws.
5
Zero Waste & Sustainable Products
-30
BioLife Plasma Services LP (considered part of BLFS.US) has implemented several waste reduction initiatives, including a $4 million investment in a Hoover, AL facility expansion and a $10 million investment in a Covington, GA facility for processing biomedical plastic waste.
1
These facilities sterilize and shred test tubes and bottles to prepare them for recycling, diverting over 1.7 million pounds of plastic in FY2025.
2
The Hoover testing lab achieved over 85% waste diversion, and the Covington site achieved over 22% waste diversion in FY2025.
3
The company is also implementing recommendations from MIT Sloan students, such as increasing training frequency and enhancing visual waste labeling.
4
Takeda, the parent company, has a zero-waste-to-landfill target by 2030.
5
No waste disposal violations were mentioned in the provided articles.